Back to today’s briefing

Story perspectives

Moderna-Merck Personalized mRNA Vaccine Cuts Melanoma Recurrence 49%

8/23/2026

35 5 Full Breakdown

Summary

Story summary

Moderna and Merck announced their personalized mRNA vaccine cut melanoma recurrence in a phase 3 trial.
The trial enrolled over 1,000 adults with resected stage IIB-IV melanoma worldwide.
After five years, the combination lowered recurrence or death risk by 49% versus pembrolizumab alone.
The same data showed a 59% reduction in distant metastasis or death versus pembrolizumab alone.

1 of 1

Story summary

Moderna and Merck announced their personalized mRNA vaccine cut melanoma recurrence in a phase 3 trial.
The trial enrolled over 1,000 adults with resected stage IIB-IV melanoma worldwide.
After five years, the combination lowered recurrence or death risk by 49% versus pembrolizumab alone.
The same data showed a 59% reduction in distant metastasis or death versus pembrolizumab alone.